Wall Street Analysts Think MercadoLibre (MELI) Is a Good Investment: Is It? — Positive
MELI Zacks Investment Research — January 09, 2026Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Is It Worth Investing in Sea Limited (SE) Based on Wall Street's Bullish Views? — Positive
SE Zacks Investment Research — January 09, 2026When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Wall Street Bulls Look Optimistic About Diversified Energy Company PLC (DEC): Should You Buy? — Positive
DEC Zacks Investment Research — January 09, 2026When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
These Nuclear Energy Stocks Are Soaring Thanks to Deals With Meta — Positive
META Investopedia — January 09, 2026Several nuclear energy stocks surged Friday morning thanks to new agreements with a Big Tech giant.
OWL INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Blue Owl Capital — Neutral
OWL GlobeNewsWire — January 09, 2026Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Blue Owl To Contact Him Directly To Discuss Their Options
Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment — Neutral
NVS GlobeNewsWire — January 09, 2026East Hanover, N.J., January 9, 2026 – Novartis, a leading global innovative medicines company, today announced plans to build its fourth US radioligand therapy (RLT) manufacturing facility in Winter Park, Florida. The built-for-purpose, state-of-the-art facility represents another milestone in the company's $23 billion US investment announced in April 2025, further expanding manufacturing capabilities to meet growing demand for these cutting-edge cancer treatments. Novartis is scaling US manufacturing to bring innovative medicines closer to patients, so treatments are researched, made, and delivered with greater speed, reliability, and access in the communities where people live. The new 35,000-square-foot facility in Winter Park, …
Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment — Neutral
NVS GlobeNewsWire — January 09, 2026Basel, January 9, 2026 – Novartis, a leading global innovative medicines company, today announced plans to build its fourth US radioligand therapy (RLT) manufacturing facility in Winter Park, Florida. The built-for-purpose, state-of-the-art facility represents another milestone in the company's $23 billion US investment announced in April 2025, further expanding manufacturing capabilities to meet growing demand for these cutting-edge cancer treatments. Novartis is scaling US manufacturing to bring innovative medicines closer to patients, so treatments are researched, made, and delivered with greater speed, reliability, and access in the communities where people live. The new 35,000-square-foot facility in Winter Park, Florida, will …
Global Ship Lease: I Sold Some, But The Stock Is Still Attractive — Neutral
GSL Seeking Alpha — January 09, 2026Global Ship Lease maintains robust profitability and cash flow through disciplined chartering and rapid debt reduction, supporting a strong balance sheet. GSL reported Q3 2025 EPS of $2.59 and nine-month free cash flow of $322M, with nearly $2B in contracted revenue underpinning future earnings. Recent acquisition of three 15-year-old vessels for $90M aligns with fleet renewal strategy and is expected to be value-accretive, given strong scrap value support.
Paramount Tells Lawmakers That Netflix-WBD Merger Is “Presumptively Unlawful” — Neutral
NFLX PSKY WBD Deadline — January 09, 2026On the day that Warner Bros. Discovery's board announced its rejection of Paramount's latest bid, the David Ellison-led conglomerate took its argument to Capitol Hill. In a letter filed with a House Judiciary antitrust subcommittee on Wednesday, Paramount's chief legal officer, Makan Delrahim, wrote to lawmakers that the Netflix-WBD combination was “presumptively unlawful.
ADI Climbs 35.7% in a Year: Should You Buy, Sell or Hold the Stock? — Positive
ADI Zacks Investment Research — January 09, 2026Analog Devices shares surge 35.7% in a year as AI-driven demand lifts industrial and communications growth, boosts data center sales and supports strong margins.
VRNS INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Varonis Systems — Neutral
VRNS Newsfile Corp — January 09, 2026Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Varonis To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Varonis between February 4, 2025 and October 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - January 9, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Varonis Systems, Inc. ("Varonis" …
Ford Bets Big on Level 3 Autonomy With $30,000 UEV Platform Push — Neutral
F Zacks Investment Research — January 09, 2026Ford plans a $30,000 UEV platform with Level 3 eyes-off BlueCruise by 2028, aiming to deliver affordable highway autonomy.
Can da Vinci 5 Expand Intuitive Surgical's TAM Beyond Core Surgeries? — Positive
ISRG Zacks Investment Research — January 09, 2026ISRG is positioning da Vinci 5 as a TAM expander, targeting cardiac surgery long term while advancing near-term regulatory steps in general surgery.
BMY Rallies 17.3% in Six Months: Buy, Sell or Hold the Stock? — Positive
BMY Zacks Investment Research — January 09, 2026Bristol Myers Squibb Company BMY has delivered a solid performance in recent months. The biotech major's shares have gained 17.3% over the past six months compared with the industry's growth of 23.4%.
3 MedTech Stocks That Crushed the S&P 500 Over the Past Year — Positive
CAH KRMD TMDX Zacks Investment Research — January 09, 2026TransMedics, KORU Medical Systems and Cardinal Health beat the S&P 500 as execution, earnings visibility and company-specific catalysts drove gains.
GAUZ Investors Have Opportunity to Lead Gauzy Ltd. Securities Fraud Lawsuit with the Schall Law Firm — Neutral
GAUZ GlobeNewsWire — January 09, 2026LOS ANGELES, Jan. 09, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Gauzy Ltd. (“Gauzy” or “the Company”) (NASDAQ: GAUZ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
FFIV INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of F5 — Neutral
FFIV GlobeNewsWire — January 09, 2026Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In F5 To Contact Him Directly To Discuss Their Options
Intuitive Surgical: An Easy 'Buy And Hold' For Long-Term Outperformance — Positive
ISRG Seeking Alpha — January 09, 2026Intuitive Surgical, Inc. dominates surgical robotics with an 80% global share and a robust, recurring-revenue business model anchored by the da Vinci platform. ISRG's installed base and procedure volumes continue double-digit growth, driven by superior clinical outcomes and high hospital switching costs. Despite premium valuation (forward P/E ~64), ISRG's pristine balance sheet, strong margins, and relentless innovation justify a long-term Buy rating.
UBER vs. BIDU: Which Stock Is Better Placed in the Promising AV Space? — Positive
BIDU UBER Zacks Investment Research — January 09, 2026Baidu edges ahead of Uber in the AV race, backed by global robotaxi rollout, stronger earnings outlook and valuation.
Stay Ahead of the Game With Bank of America (BAC) Q4 Earnings: Wall Street's Insights on Key Metrics — Neutral
BAC Zacks Investment Research — January 09, 2026Evaluate the expected performance of Bank of America (BAC) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
